Inhibition of mast cell infiltration in an LL‐37‐induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. Issue 11 (15th August 2017)

• Record Type: Journal Article
• Authors: Kim, Miri; Kim, Jongsic; Jeong, Seo‐won; Jo, Hyunmu; Woo, Yu Ri; Park, Hyun Jeong
• Is Part Of: Experimental dermatology. Volume 26:Issue 11(2017)
• Page Start: 1143
• Page End: 1145
• Publication Date: 2017-08-15
• Subjects: brimonidine -- mast cell -- rosacea; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/exd.13381
• Languages: English
• ISSNs: 0906-6705

Abstract

Abstract: Brimonidine is a highly selective α2‐adrenergic receptor agonist approved by the FDA for the treatment of rosacea. Rosacea is a major clinical disease with vasodilatation and rash on the centre of the face, and that brimonidine as a vasoconstrictor can act as a remedy for rosacea. However, there is no study of how brimonidine has an effect on rosacea‐related immune cells or mechanisms in the skin to improve rosacea. In this study, we observed that clinical features of rosacea induced by LL‐37 in Balb/c mice were improved after the application of brimonidine gel, and we also showed a marked decrease in the number of inflammatory cells, especially mast cells (MCs) histologically. Furthermore, we confirmed that mRNA levels of MC enzymes increased by LL‐37 were reduced by brimonidine gel. To our knowledge, we first found that brimonidine has a mechanism of treating rosacea by reducing the number and mRNA levels of MC‐specific enzymes, an important immune cell in the pathogenesis of rosacea.